Amifampridine
| Amifampridine | |
|---|---|
| Salts [] | |
|---|---|
| Amifampridine phosphate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 109.13 g/mol [1] |
| Melting point | 229 ± 2 [1] |
| Solubility | freely soluble in water, and slightly soluble in solvents ethanol, methanol and acetic acid [1] |
| Predicted LogP | -0.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C5H7N3 |
| IUPAC name | pyridine-3,4-diamine |
| SMILES | C1=CN=CC(=C1N)N |
| InChI | InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8) |
| InChIKey | OYTKINVCDFNREN-UHFFFAOYSA-N |
| CAS number | 54-96-6 |
| UNII | RU4S6E2G0J |
| PubChem CID | 5918 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2.5 hours (amifampridine), 4 hours (3-N-acetyl­amifampridine) |
| Metabolism | Acetylation to 3-N-acetyl­amifampridine |
| Excretion | Kidney (19% unmetabolized, 74–81% 3-N-acetyl­amifampridine) |
| Routes of administration | By mouth |
Amifampridine (also known as 3,4-Pyridinediamine, 4,5-Diaminopyridine, 3,4-dap, Pyridine, 3,4-diamino-, amifampridina, SC10, 3,4 Diaminopyridine, amifampridinum, 5-22-11-00266 (Beilstein Handbook Reference) or N07xx05).
Chemistry
Salts []
Stereochemistry []
Amifampridine is achiral.
Druglikeness
Lipinski's rule of five
Amifampridine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- other nervous system drugs (N07)
- other nervous system drugs (N07X)
- other nervous system drugs (N07XX)
- amifampridine (N07XX05)
MeSH Classification
Mechanism of action []
Amifampridine is a symptomatic treatment that increases acetylcholine concentrations at the neuromuscular junction. It selectively blocks presynaptic fast voltage-gated potassium channels, thereby prolonging cell membrane depolarization and action potential, and augmenting calcium transport into the nerve endings. Increased intracellular calcium enhances the exocytosis of acetylcholine-containing vesicles and enhances impulse transmission at central, autonomic, and neuromuscular synapses. Amifampridine improves muscle strength and resting compound muscle action potential (CMAP) amplitudes with an overall weighted mean difference of 1.69 mV. [1]
Legal status []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5918, Amifampridine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5918
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Amifampridine. UNII: RU4S6E2G0J. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/RU4S6E2G0J
Ruzurgi APMDS. Therapeutic Goods Administration (TGA). 24 September 2021. https://www.tga.gov.au/resources/auspmd/ruzurgi
Summary Basis of Decision (SBD) for Firdapse. Health Canada. 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00503&lang=en
Summary Basis of Decision (SBD) for Ruzurgi. Health Canada. 23 October 2014. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00501&lang=en
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 11:01:02 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 11:00:58 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 11:00:58 |
| gsrs | ok | 2026-11-20 11:00:58 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0246022) | 2026-11-20 11:00:58 |
| kegg | ok | 2026-11-20 11:00:59 |
| pubchem | ok | 2026-11-20 11:00:57 |
| missing (no r/tripreports posts mention it) | 2026-11-20 11:00:58 | |
| sider | missing (not in SIDER) | 2026-11-20 11:00:58 |
| structure | ok | 2026-11-20 11:00:58 |
| wikipedia | ok | 2026-11-20 11:00:58 |